Sartorius Stedim Biotech Share Price
Equities
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 214.00 EUR | -0.56% |
|
+5.42% | +13.41% |
| 23/10 | SARTORIUS STEDIM BIOTECH : Consumables underpin solid Q3 2025 |  |
| 20/10 | SARTORIUS STEDIM BIOTECH : Goldman Sachs maintains a Buy rating | ZD |
| Capitalization | 2.08TCr 2.43TCr 1.95TCr 1.82TCr 3.39TCr 2,18100Cr 3.67TCr 23TCr 8.82TCr 1,03100Cr 9.11TCr 8.92TCr 3,75800Cr | P/E ratio 2025 * |
63.9x | P/E ratio 2026 * | 47.6x |
|---|---|---|---|---|---|
| Enterprise value | 2.29TCr 2.67TCr 2.14TCr 2TCr 3.73TCr 2,40000Cr 4.04TCr 25TCr 9.7TCr 1,13400Cr 10TCr 9.81TCr 4,13500Cr | EV / Sales 2025 * |
7.7x | EV / Sales 2026 * | 6.97x |
| Free-Float |
30.28% | Yield 2025 * |
0.38% | Yield 2026 * | 0.48% |
Last Transcript: Sartorius Stedim Biotech
| 1 day | -0.56% | ||
| 1 week | +5.42% | ||
| Current month | +3.23% | ||
| 1 month | +6.79% | ||
| 3 months | +25.18% | ||
| 6 months | +10.48% | ||
| Current year | +13.41% |
| 1 week | 205.5 |  | 217.2 |
| 1 month | 182.75 | | 217.2 |
| Current year | 148.75 | | 239.8 |
| 1 year | 148.75 | | 239.8 |
| 3 years | 139.1 | | 358.8 |
| 5 years | 139.1 | | 551 |
| 10 years | 50.1 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 50 | 28/03/2023 |
| Chief Tech/Sci/R&D Officer | 61 | 08/09/2011 | |
Petra Kirchhoff
IRC | Investor Relations Contact | 56 | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 07/04/2015 | |
Susan Dexter
BRD | Director/Board Member | 69 | 07/04/2015 |
Lothar Kappich
BRD | Director/Board Member | 68 | 14/09/2017 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.42% | 26 M€ | +11.91% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.56% | +5.42% | +18.33% | -37.04% | 2.44TCr | |
| +0.09% | -2.44% | +8.13% | +16.01% | 22TCr | |
| +0.02% | -2.89% | +19.54% | +28.10% | 13TCr | |
| +0.69% | -8.38% | +35.95% | +94.05% | 6.5TCr | |
| +0.10% | -0.07% | -12.50% | -23.23% | 5.52TCr | |
| -0.94% | +0.72% | +17.40% | +69.56% | 5.12TCr | |
| +0.62% | -2.18% | +20.15% | +36.01% | 2.55TCr | |
| +0.62% | +4.35% | -19.45% | -44.75% | 2.53TCr | |
| -2.10% | -2.83% | -23.93% | +17.49% | 2.26TCr | |
| +2.72% | -3.33% | +17.35% | +2.55% | 2.16TCr | |
| Average | +0.12% | -1.39% | +8.10% | +15.88% | 6.4TCr | |
| Weighted average by Cap. | +0.08% | -2.29% | +11.21% | +23.29% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 297.66Cr 347.12Cr 278.37Cr 259.98Cr 484.07Cr 31TCr 524.36Cr 3.27TCr 1.26TCr 15TCr 1.3TCr 1.28TCr 54TCr | 325.85Cr 380Cr 304.74Cr 284.61Cr 529.92Cr 34TCr 574.03Cr 3.58TCr 1.38TCr 16TCr 1.43TCr 1.4TCr 59TCr |
| Net income | 32Cr 37Cr 30Cr 28Cr 52Cr 3.33TCr 56Cr 349.08Cr 134.7Cr 1.57TCr 139.26Cr 136.29Cr 5.74TCr | 43Cr 50Cr 40Cr 38Cr 70Cr 4.53TCr 76Cr 474.34Cr 183.04Cr 2.14TCr 189.23Cr 185.2Cr 7.8TCr |
| Net Debt | 208.95Cr 243.67Cr 195.41Cr 182.5Cr 339.81Cr 22TCr 368.09Cr 2.29TCr 884.61Cr 10TCr 914.56Cr 895.06Cr 38TCr | 189.84Cr 221.38Cr 177.54Cr 165.81Cr 308.72Cr 20TCr 334.42Cr 2.08TCr 803.69Cr 9.4TCr 830.9Cr 813.18Cr 34TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/25/04 | 214.00 € | -0.56% | 71,723 |
| 03/25/03 | 215.20 € | +3.76% | 1,12,643 |
| 02/25/02 | 207.40 € | -0.34% | 91,251 |
| 01/25/01 | 208.10 € | +0.39% | 69,126 |
| 28/25/28 | 207.30 € | +2.12% | 71,073 |
Real-time Euronext Paris, December 04, 2025 at 10:25 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition